---
document_datetime: 2025-12-02 05:17:11
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/xgeva.html
document_name: xgeva.html
version: success
processing_time: 0.1416273
conversion_datetime: 2025-12-28 08:25:42.182648
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Xgeva

[RSS](/en/individual-human-medicine.xml/65702)

##### Authorised

This medicine is authorised for use in the European Union

denosumab Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Xgeva](#news-on)
- [More information on Xgeva](#more-information-on-xgeva-1060)
- [Product information - with tracked changes](#product-information-with-tracked-changes-78463)
- [More information on Xgeva](#related-medicines)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Xgeva is a medicine used to prevent bone complications in adults with advanced cancer that has spread to the bone. These complications include fractures (breaks in the bone), spinal compression (pressure on the spinal cord caused by damage to the surrounding bone), or bone problems requiring radiotherapy (treatment with radiation) or surgery.

Xgeva is also used to treat a type of bone cancer called giant cell tumour of bone in adults and adolescents whose bones have fully developed. It is used in patients who cannot be treated by surgery or in whom surgery is likely to cause complications.

Xgeva contains the active substance denosumab.

Expand section

Collapse section

## How is Xgeva used?

Xgeva can only be obtained with a prescription. It is available as a solution for injection under the skin.

To prevent bone complications in cancer that has spread to the bone, 120 mg is given once every 4 weeks as a single injection under the skin in the thigh, abdomen (belly) or upper arm.

In patients with giant cell tumour of bone, 120 mg is injected under the skin once a week for 3 weeks, and then once every 4 weeks.

Patients should take calcium and vitamin D supplements while being treated with Xgeva.

For more information about using Xgeva, see the package leaflet or contact a doctor or pharmacist.

## How does Xgeva work?

The active substance in Xgeva, denosumab, is a monoclonal antibody which has been designed to recognise and attach to a protein called RANKL. This protein activates osteoclasts, the cells in the body that are involved in breaking down bone tissue. By attaching to RANKL and blocking it, denosumab reduces the formation and activity of the osteoclasts. This reduces the loss of bone, making fractures and other serious bone complications less likely. The cells in giant cell tumour of bone are also activated via RANKL, and treatment with denosumab prevents them from growing and breaking down bone, allowing normal bone to replace the tumour.

## What benefits of Xgeva have been shown in studies?

**Prevention of bone complications**

Xgeva was compared with zoledronic acid (another medicine used to prevent bone complications) in four main studies in patients with different types of cancer which had spread to the bone.

All the studies looked at the risk of patients having a first 'skeletal-related event' (such as a fracture, pressure on the spinal cord or the need for radiotherapy or surgery to the bone) during the study period by measuring how long it took for this event to happen.

The first study involved 2,046 patients with breast cancer and the second study involved 1,901 men with prostate cancer which did not respond to hormonal treatment. In these studies, Xgeva reduced the risk of developing a first skeletal-related event by 18% compared with zoledronic acid.

The third study involved 1,776 patients with advanced solid tumours in various parts of the body or with multiple myeloma (a cancer of the bone marrow). In this study, Xgeva reduced the risk of developing a first skeletal-related event by 16% compared with zoledronic acid.

In another study involving 1,718 patients with newly diagnosed multiple myeloma, Xgeva was as effective as zoledronic acid in delaying the patients' first skeletal-related event.

**Treatment of giant cell tumour of bone**

In patients with giant cell tumour of bone, Xgeva was effective in controlling the disease. Two main studies looked at the effect of Xgeva in adults or full-grown adolescents with giant cell tumour of bone that was unsuitable for surgery or in whom surgery would have resulted in severe complications like amputation of a limb.

The first study involved 37 patients, 86 % of whom responded to treatment with Xgeva. A response to treatment was defined as elimination of at least 90% of the giant cells or no progression of the condition after 25 weeks of treatment.

In the second study which involved 507 patients treatment with Xgeva prevented surgery in about half (109 of 225) of the group in whom surgery would have resulted in complications. Of the remainder, 84 were able to have less extensive surgery than previously planned. About 20% of patients were able to have complete surgical removal of the cancer. For 31 patients their disease got worse during treatment.

## What are the risks associated with Xgeva?

The most common side effects with Xgeva (seen in more than 1 patient in 10) are hypocalcaemia (low levels of calcium in the blood), pain in the muscles and bones, dyspnoea (difficulty breathing) and diarrhoea. Other common side effects (seen in up to 1 patient in 10) are development of another form of cancer in patients with advanced cancer, hypophosphataemia (low levels of phosphate in the blood), excessive sweating, tooth loss and osteonecrosis in the jaw (damage to the bones of the jaw, which could lead to pain, sores in the mouth and loose teeth).

Xgeva must not be used in patients with wounds from dental or mouth surgery have not yet healed, or in people with severe, untreated hypocalcaemia.

For the full list of side effects and restrictions with Xgeva, see the package leaflet.

## Why is Xgeva authorised in the EU?

The European Medicines Agency decided that Xgeva's benefits are greater than its risks for patients with cancers that has spread to the bone, and it can be authorised for use in the EU. The Agency noted that there is a need for an effective treatment for bone disease in advanced cancer, particularly for patients with kidney problems since currently available treatments can be toxic for the kidneys. The Agency considered that Xgeva was effective in preventing bone-related events and was less toxic to the kidneys and easier to use than existing treatments.

For patients with giant cell tumour of bone the possibility of complete surgical removal of the tumour after treatment and the reduction in extent of the surgery in some patients were considered clinically important. The Agency considered that the benefits of Xgeva in giant cell tumour of bone were greater than the risks, and recommended that it be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Xgeva?

The company that markets Xgeva will provide a card to inform patients about the risk of osteonecrosis of the jaw and to instruct them to contact their doctor if they have symptoms.

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Xgeva have also been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Xgeva are continuously monitored. Side effects reported with Xgeva are carefully evaluated and any necessary action taken to protect patients.

## Other information about Xgeva

Xgeva received a marketing authorisation valid throughout the EU on 13 July 2011.

Xgeva: EPAR - Medicine overview

Reference Number: EMA/440086/2019

English (EN) (81 KB - PDF)

**First published:** 15/08/2011

**Last updated:** 05/08/2019

[View](/en/documents/overview/xgeva-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-860)

български (BG) (108.45 KB - PDF)

**First published:**

15/08/2011

**Last updated:**

05/08/2019

[View](/bg/documents/overview/xgeva-epar-medicine-overview_bg.pdf)

español (ES) (79.29 KB - PDF)

**First published:**

15/08/2011

**Last updated:**

05/08/2019

[View](/es/documents/overview/xgeva-epar-medicine-overview_es.pdf)

čeština (CS) (105.65 KB - PDF)

**First published:**

15/08/2011

**Last updated:**

05/08/2019

[View](/cs/documents/overview/xgeva-epar-medicine-overview_cs.pdf)

dansk (DA) (77.88 KB - PDF)

**First published:**

15/08/2011

**Last updated:**

05/08/2019

[View](/da/documents/overview/xgeva-epar-medicine-overview_da.pdf)

Deutsch (DE) (80.68 KB - PDF)

**First published:**

15/08/2011

**Last updated:**

05/08/2019

[View](/de/documents/overview/xgeva-epar-medicine-overview_de.pdf)

eesti keel (ET) (77.86 KB - PDF)

**First published:**

15/08/2011

**Last updated:**

05/08/2019

[View](/et/documents/overview/xgeva-epar-medicine-overview_et.pdf)

ελληνικά (EL) (114.75 KB - PDF)

**First published:**

15/08/2011

**Last updated:**

05/08/2019

[View](/el/documents/overview/xgeva-epar-medicine-overview_el.pdf)

français (FR) (81.24 KB - PDF)

**First published:**

15/08/2011

**Last updated:**

05/08/2019

[View](/fr/documents/overview/xgeva-epar-medicine-overview_fr.pdf)

hrvatski (HR) (101.74 KB - PDF)

**First published:**

15/08/2011

**Last updated:**

05/08/2019

[View](/hr/documents/overview/xgeva-epar-medicine-overview_hr.pdf)

italiano (IT) (78.46 KB - PDF)

**First published:**

15/08/2011

**Last updated:**

05/08/2019

[View](/it/documents/overview/xgeva-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (103.98 KB - PDF)

**First published:**

15/08/2011

**Last updated:**

05/08/2019

[View](/lv/documents/overview/xgeva-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (104.49 KB - PDF)

**First published:**

15/08/2011

**Last updated:**

05/08/2019

[View](/lt/documents/overview/xgeva-epar-medicine-overview_lt.pdf)

magyar (HU) (103.09 KB - PDF)

**First published:**

15/08/2011

**Last updated:**

05/08/2019

[View](/hu/documents/overview/xgeva-epar-medicine-overview_hu.pdf)

Malti (MT) (107.2 KB - PDF)

**First published:**

15/08/2011

**Last updated:**

05/08/2019

[View](/mt/documents/overview/xgeva-epar-medicine-overview_mt.pdf)

Nederlands (NL) (78.35 KB - PDF)

**First published:**

15/08/2011

**Last updated:**

05/08/2019

[View](/nl/documents/overview/xgeva-epar-medicine-overview_nl.pdf)

polski (PL) (106.77 KB - PDF)

**First published:**

15/08/2011

**Last updated:**

05/08/2019

[View](/pl/documents/overview/xgeva-epar-medicine-overview_pl.pdf)

português (PT) (79.01 KB - PDF)

**First published:**

15/08/2011

**Last updated:**

05/08/2019

[View](/pt/documents/overview/xgeva-epar-medicine-overview_pt.pdf)

română (RO) (103.95 KB - PDF)

**First published:**

15/08/2011

**Last updated:**

05/08/2019

[View](/ro/documents/overview/xgeva-epar-medicine-overview_ro.pdf)

slovenčina (SK) (105.34 KB - PDF)

**First published:**

15/08/2011

**Last updated:**

05/08/2019

[View](/sk/documents/overview/xgeva-epar-medicine-overview_sk.pdf)

slovenščina (SL) (100.24 KB - PDF)

**First published:**

15/08/2011

**Last updated:**

05/08/2019

[View](/sl/documents/overview/xgeva-epar-medicine-overview_sl.pdf)

Suomi (FI) (77.48 KB - PDF)

**First published:**

15/08/2011

**Last updated:**

05/08/2019

[View](/fi/documents/overview/xgeva-epar-medicine-overview_fi.pdf)

svenska (SV) (78.81 KB - PDF)

**First published:**

15/08/2011

**Last updated:**

05/08/2019

[View](/sv/documents/overview/xgeva-epar-medicine-overview_sv.pdf)

Xgeva : Risk-managment-plan

English (EN) (9.62 MB - PDF)

**First published:** 17/07/2023

**Last updated:** 04/09/2024

[View](/en/documents/rmp/xgeva-risk-managment-plan_en.pdf)

## Product information

Xgeva : EPAR - Product Information

English (EN) (798.38 KB - PDF)

**First published:** 15/08/2011

**Last updated:** 29/07/2025

[View](/en/documents/product-information/xgeva-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-863)

български (BG) (957.73 KB - PDF)

**First published:**

15/08/2011

**Last updated:**

29/07/2025

[View](/bg/documents/product-information/xgeva-epar-product-information_bg.pdf)

español (ES) (922.33 KB - PDF)

**First published:**

15/08/2011

**Last updated:**

29/07/2025

[View](/es/documents/product-information/xgeva-epar-product-information_es.pdf)

čeština (CS) (986.28 KB - PDF)

**First published:**

15/08/2011

**Last updated:**

29/07/2025

[View](/cs/documents/product-information/xgeva-epar-product-information_cs.pdf)

dansk (DA) (911.51 KB - PDF)

**First published:**

15/08/2011

**Last updated:**

29/07/2025

[View](/da/documents/product-information/xgeva-epar-product-information_da.pdf)

Deutsch (DE) (945.73 KB - PDF)

**First published:**

15/08/2011

**Last updated:**

29/07/2025

[View](/de/documents/product-information/xgeva-epar-product-information_de.pdf)

eesti keel (ET) (894.31 KB - PDF)

**First published:**

15/08/2011

**Last updated:**

29/07/2025

[View](/et/documents/product-information/xgeva-epar-product-information_et.pdf)

ελληνικά (EL) (963.76 KB - PDF)

**First published:**

15/08/2011

**Last updated:**

29/07/2025

[View](/el/documents/product-information/xgeva-epar-product-information_el.pdf)

français (FR) (967.67 KB - PDF)

**First published:**

15/08/2011

**Last updated:**

29/07/2025

[View](/fr/documents/product-information/xgeva-epar-product-information_fr.pdf)

hrvatski (HR) (925.16 KB - PDF)

**First published:**

15/08/2011

**Last updated:**

29/07/2025

[View](/hr/documents/product-information/xgeva-epar-product-information_hr.pdf)

íslenska (IS) (896.97 KB - PDF)

**First published:**

15/08/2011

**Last updated:**

29/07/2025

[View](/is/documents/product-information/xgeva-epar-product-information_is.pdf)

italiano (IT) (927.99 KB - PDF)

**First published:**

15/08/2011

**Last updated:**

29/07/2025

[View](/it/documents/product-information/xgeva-epar-product-information_it.pdf)

latviešu valoda (LV) (928.82 KB - PDF)

**First published:**

15/08/2011

**Last updated:**

29/07/2025

[View](/lv/documents/product-information/xgeva-epar-product-information_lv.pdf)

lietuvių kalba (LT) (948.51 KB - PDF)

**First published:**

15/08/2011

**Last updated:**

29/07/2025

[View](/lt/documents/product-information/xgeva-epar-product-information_lt.pdf)

magyar (HU) (960.28 KB - PDF)

**First published:**

15/08/2011

**Last updated:**

29/07/2025

[View](/hu/documents/product-information/xgeva-epar-product-information_hu.pdf)

Malti (MT) (1.04 MB - PDF)

**First published:**

15/08/2011

**Last updated:**

29/07/2025

[View](/mt/documents/product-information/xgeva-epar-product-information_mt.pdf)

Nederlands (NL) (909.45 KB - PDF)

**First published:**

15/08/2011

**Last updated:**

29/07/2025

[View](/nl/documents/product-information/xgeva-epar-product-information_nl.pdf)

norsk (NO) (907.16 KB - PDF)

**First published:**

15/08/2011

**Last updated:**

29/07/2025

[View](/no/documents/product-information/xgeva-epar-product-information_no.pdf)

polski (PL) (960.48 KB - PDF)

**First published:**

15/08/2011

**Last updated:**

29/07/2025

[View](/pl/documents/product-information/xgeva-epar-product-information_pl.pdf)

português (PT) (913.42 KB - PDF)

**First published:**

15/08/2011

**Last updated:**

29/07/2025

[View](/pt/documents/product-information/xgeva-epar-product-information_pt.pdf)

română (RO) (955.01 KB - PDF)

**First published:**

15/08/2011

**Last updated:**

29/07/2025

[View](/ro/documents/product-information/xgeva-epar-product-information_ro.pdf)

slovenčina (SK) (987.64 KB - PDF)

**First published:**

15/08/2011

**Last updated:**

29/07/2025

[View](/sk/documents/product-information/xgeva-epar-product-information_sk.pdf)

slovenščina (SL) (916.83 KB - PDF)

**First published:**

15/08/2011

**Last updated:**

29/07/2025

[View](/sl/documents/product-information/xgeva-epar-product-information_sl.pdf)

Suomi (FI) (901.41 KB - PDF)

**First published:**

15/08/2011

**Last updated:**

29/07/2025

[View](/fi/documents/product-information/xgeva-epar-product-information_fi.pdf)

svenska (SV) (896.72 KB - PDF)

**First published:**

15/08/2011

**Last updated:**

29/07/2025

[View](/sv/documents/product-information/xgeva-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** VR/0000280127 29/07/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Xgeva : EPAR - All Authorised presentations

English (EN) (51.06 KB - PDF)

**First published:** 15/08/2011

**Last updated:** 29/04/2024

[View](/en/documents/all-authorised-presentations/xgeva-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-223)

български (BG) (58.86 KB - PDF)

**First published:**

15/08/2011

**Last updated:**

29/04/2024

[View](/bg/documents/all-authorised-presentations/xgeva-epar-all-authorised-presentations_bg.pdf)

español (ES) (51.7 KB - PDF)

**First published:**

15/08/2011

**Last updated:**

29/04/2024

[View](/es/documents/all-authorised-presentations/xgeva-epar-all-authorised-presentations_es.pdf)

čeština (CS) (54.51 KB - PDF)

**First published:**

15/08/2011

**Last updated:**

29/04/2024

[View](/cs/documents/all-authorised-presentations/xgeva-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (56.7 KB - PDF)

**First published:**

15/08/2011

**Last updated:**

29/04/2024

[View](/da/documents/all-authorised-presentations/xgeva-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (56.56 KB - PDF)

**First published:**

15/08/2011

**Last updated:**

29/04/2024

[View](/de/documents/all-authorised-presentations/xgeva-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (49.44 KB - PDF)

**First published:**

15/08/2011

**Last updated:**

29/04/2024

[View](/et/documents/all-authorised-presentations/xgeva-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (53.62 KB - PDF)

**First published:**

15/08/2011

**Last updated:**

29/04/2024

[View](/el/documents/all-authorised-presentations/xgeva-epar-all-authorised-presentations_el.pdf)

français (FR) (51.38 KB - PDF)

**First published:**

15/08/2011

**Last updated:**

29/04/2024

[View](/fr/documents/all-authorised-presentations/xgeva-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (51.41 KB - PDF)

**First published:**

15/08/2011

**Last updated:**

29/04/2024

[View](/hr/documents/all-authorised-presentations/xgeva-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (52.22 KB - PDF)

**First published:**

15/08/2011

**Last updated:**

29/04/2024

[View](/is/documents/all-authorised-presentations/xgeva-epar-all-authorised-presentations_is.pdf)

italiano (IT) (69.35 KB - PDF)

**First published:**

15/08/2011

**Last updated:**

29/04/2024

[View](/it/documents/all-authorised-presentations/xgeva-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (53.41 KB - PDF)

**First published:**

15/08/2011

**Last updated:**

29/04/2024

[View](/lv/documents/all-authorised-presentations/xgeva-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (55.3 KB - PDF)

**First published:**

15/08/2011

**Last updated:**

29/04/2024

[View](/lt/documents/all-authorised-presentations/xgeva-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (53.18 KB - PDF)

**First published:**

15/08/2011

**Last updated:**

29/04/2024

[View](/hu/documents/all-authorised-presentations/xgeva-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (56.39 KB - PDF)

**First published:**

15/08/2011

**Last updated:**

29/04/2024

[View](/mt/documents/all-authorised-presentations/xgeva-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (50.57 KB - PDF)

**First published:**

15/08/2011

**Last updated:**

29/04/2024

[View](/nl/documents/all-authorised-presentations/xgeva-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (56.18 KB - PDF)

**First published:**

15/08/2011

**Last updated:**

29/04/2024

[View](/no/documents/all-authorised-presentations/xgeva-epar-all-authorised-presentations_no.pdf)

polski (PL) (53.98 KB - PDF)

**First published:**

15/08/2011

**Last updated:**

29/04/2024

[View](/pl/documents/all-authorised-presentations/xgeva-epar-all-authorised-presentations_pl.pdf)

português (PT) (54.45 KB - PDF)

**First published:**

15/08/2011

**Last updated:**

29/04/2024

[View](/pt/documents/all-authorised-presentations/xgeva-epar-all-authorised-presentations_pt.pdf)

română (RO) (73.96 KB - PDF)

**First published:**

15/08/2011

**Last updated:**

29/04/2024

[View](/ro/documents/all-authorised-presentations/xgeva-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (56.84 KB - PDF)

**First published:**

15/08/2011

**Last updated:**

29/04/2024

[View](/sk/documents/all-authorised-presentations/xgeva-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (52.64 KB - PDF)

**First published:**

15/08/2011

**Last updated:**

29/04/2024

[View](/sl/documents/all-authorised-presentations/xgeva-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (68.6 KB - PDF)

**First published:**

15/08/2011

**Last updated:**

29/04/2024

[View](/fi/documents/all-authorised-presentations/xgeva-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (54.25 KB - PDF)

**First published:**

15/08/2011

**Last updated:**

29/04/2024

[View](/sv/documents/all-authorised-presentations/xgeva-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Xgeva Active substance denosumab International non-proprietary name (INN) or common name denosumab Therapeutic area (MeSH)

- Giant Cell Tumor of Bone
- Neoplasms, Bone Tissue

Anatomical therapeutic chemical (ATC) code M05BX04

### Pharmacotherapeutic group

Drugs for treatment of bone diseases

### Therapeutic indication

Prevention of skeletal related events (pathological fracture, radiation to bone, spinal cord compression or surgery to bone) in adults with advanced malignancies involving bone (see section 5.1).

Treatment of adults and skeletally mature adolescents with giant cell tumour of bone that is unresectable or where surgical resection is likely to result in severe morbidity.

## Authorisation details

EMA product number EMEA/H/C/002173 Marketing authorisation holder

Amgen Europe B.V.

Minervum 7061

Opinion adopted 19/05/2011 Marketing authorisation issued 13/07/2011 Revision 27

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Xgeva : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (141.57 KB - PDF)

**First published:** 29/07/2025

[View](/en/documents/procedural-steps-after/xgeva-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Xgeva : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (253.58 KB - PDF)

**First published:** 30/05/2012

**Last updated:** 29/07/2025

[View](/en/documents/procedural-steps-after/xgeva-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

Xgeva-H-C-002173-II-0069 : EPAR - Assessment Report - Variation

Adopted

Reference Number: EMA/615456/2019

English (EN) (2.51 MB - PDF)

**First published:** 24/03/2020

[View](/en/documents/variation-report/xgeva-h-c-002173-ii-0069-epar-assessment-report-variation_en.pdf)

Xgeva-H-C-PSUSA-00009119-201709 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Adopted

Reference Number: EMA/300573/2019

English (EN) (68.63 KB - PDF)

**First published:** 05/06/2019

[View](/en/documents/scientific-conclusion/xgeva-h-c-psusa-00009119-201709-epar-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation_en.pdf)

Xgeva-H-C-2173-II-0055 : EPAR - Assessment Report - Variation

Adopted

Reference Number: EMA/CHMP/333703/2018

English (EN) (2.71 MB - PDF)

**First published:** 24/05/2018

**Last updated:** 24/05/2018

[View](/en/documents/variation-report/xgeva-h-c-2173-ii-0055-epar-assessment-report-variation_en.pdf)

CHMP post-authorisation summary of positive opinion for Xgeva (II-55)

Adopted

Reference Number: EMA/86370/2018

English (EN) (67.77 KB - PDF)

**First published:** 23/02/2018

**Last updated:** 23/02/2018

[View](/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-xgeva-ii-55_en.pdf)

Xgeva-H-C-002173-II-56 : EPAR - Assessment Report - Variation

Adopted

Reference Number: EMA/848543/2017

English (EN) (240.8 KB - PDF)

**First published:** 25/01/2018

**Last updated:** 25/01/2018

[View](/en/documents/variation-report/xgeva-h-c-002173-ii-56-epar-assessment-report-variation_en.pdf)

Xgeva-PSUSA-00009119-201609 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Reference Number: EMA/502080/2017

English (EN) (60.24 KB - PDF)

**First published:** 02/08/2017

**Last updated:** 02/08/2017

[View](/en/documents/scientific-conclusion/xgeva-psusa-00009119-201609-epar-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation_en.pdf)

Xgeva-H-C-PSUSA-00009119-201409 : EPAR - Scientific conclusions and grounds for recommending the variation to the terms of the marketing authorisation

Reference Number: EMA/CHMP/509036/2015

English (EN) (68.53 KB - PDF)

**First published:** 19/08/2015

**Last updated:** 19/08/2015

[View](/en/documents/scientific-conclusion/xgeva-h-c-psusa-00009119-201409-epar-scientific-conclusions-and-grounds-recommending-variation-terms-marketing-authorisation_en.pdf)

Xgeva-H-C-2173-II-0016 : EPAR - Assessment Report - Variation

Adopted

Reference Number: EMA/CHMP/468730/2014

English (EN) (1.71 MB - PDF)

**First published:** 29/10/2014

**Last updated:** 29/10/2014

[View](/en/documents/variation-report/xgeva-h-c-2173-ii-0016-epar-assessment-report-variation_en.pdf)

CHMP post-authorisation summary of positive opinion for Xgeva

Adopted

Reference Number: EMA/CHMP/445632/2014

English (EN) (67.82 KB - PDF)

**First published:** 25/07/2014

**Last updated:** 25/07/2014

[View](/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-xgeva_en.pdf)

Xgeva-H-C-2173-II-0011 : EPAR - Assessment Report - Variation

Adopted

Reference Number: EMA/CHMP/661174/2013

English (EN) (927.01 KB - PDF)

**First published:** 03/01/2014

**Last updated:** 03/01/2014

[View](/en/documents/variation-report/xgeva-h-c-2173-ii-0011-epar-assessment-report-variation_en.pdf)

## Initial marketing authorisation documents

Xgeva : EPAR - Public assessment report

Adopted

English (EN) (2.45 MB - PDF)

**First published:** 15/08/2011

**Last updated:** 15/08/2011

[View](/en/documents/assessment-report/xgeva-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Xgeva

Adopted

Reference Number: EMA/CHMP/383964/2011

English (EN) (63.34 KB - PDF)

**First published:** 20/05/2011

**Last updated:** 20/05/2011

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-xgeva_en.pdf)

#### News on Xgeva

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 19-22 February 2018](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-19-22-february-2018) 23/02/2018

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 23-26 January 2017](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-23-26-january-2017) 27/01/2017

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 21-24 July 2014](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-21-24-july-2014) 25/07/2014

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 21-24 October 2013](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-21-24-october-2013) 25/10/2013

#### More information on Xgeva

Questions and answers on the outcome of an application for Xgeva to be used in patients with castration-resistant prostate cancer at high risk of spreading to the bones

Adopted

Reference Number: EMA/655170/2013

English (EN) (75.73 KB - PDF)

**First published:** 25/10/2013

**Last updated:** 25/10/2013

[View](/en/documents/medicine-qa/questions-and-answers-outcome-application-xgeva-be-used-patients-castration-resistant-prostate-cancer-high-risk-spreading-bones_en.pdf)

#### Product information - with tracked changes

The approved product information for this medicine is available below showing the changes since the previous procedure affecting the product information. The same document without tracked changes is above under 'Product information'.

Xgeva : EPAR - Product information - tracked changes

English (EN) (5.44 MB - DOCX)

**First published:** 29/07/2025

[View](/en/documents/product-information-tracked-changes/xgeva-epar-product-information-tracked-changes_en.docx)

[Other languages (24)](#file-language-dropdown-66)

български (BG) (5.46 MB - DOCX)

**First published:**

29/07/2025

[View](/bg/documents/product-information-tracked-changes/xgeva-epar-product-information-tracked-changes_bg.docx)

español (ES) (5.45 MB - DOCX)

**First published:**

29/07/2025

[View](/es/documents/product-information-tracked-changes/xgeva-epar-product-information-tracked-changes_es.docx)

čeština (CS) (5.45 MB - DOCX)

**First published:**

29/07/2025

[View](/cs/documents/product-information-tracked-changes/xgeva-epar-product-information-tracked-changes_cs.docx)

dansk (DA) (5.44 MB - DOCX)

**First published:**

29/07/2025

[View](/da/documents/product-information-tracked-changes/xgeva-epar-product-information-tracked-changes_da.docx)

Deutsch (DE) (5.45 MB - DOCX)

**First published:**

29/07/2025

[View](/de/documents/product-information-tracked-changes/xgeva-epar-product-information-tracked-changes_de.docx)

eesti keel (ET) (5.44 MB - DOCX)

**First published:**

29/07/2025

[View](/et/documents/product-information-tracked-changes/xgeva-epar-product-information-tracked-changes_et.docx)

ελληνικά (EL) (5.46 MB - DOCX)

**First published:**

29/07/2025

[View](/el/documents/product-information-tracked-changes/xgeva-epar-product-information-tracked-changes_el.docx)

français (FR) (5.45 MB - DOCX)

**First published:**

29/07/2025

[View](/fr/documents/product-information-tracked-changes/xgeva-epar-product-information-tracked-changes_fr.docx)

hrvatski (HR) (5.44 MB - DOCX)

**First published:**

29/07/2025

[View](/hr/documents/product-information-tracked-changes/xgeva-epar-product-information-tracked-changes_hr.docx)

íslenska (IS) (5.44 MB - DOCX)

**First published:**

29/07/2025

[View](/is/documents/product-information-tracked-changes/xgeva-epar-product-information-tracked-changes_is.docx)

italiano (IT) (5.45 MB - DOCX)

**First published:**

29/07/2025

[View](/it/documents/product-information-tracked-changes/xgeva-epar-product-information-tracked-changes_it.docx)

latviešu valoda (LV) (5.44 MB - DOCX)

**First published:**

29/07/2025

[View](/lv/documents/product-information-tracked-changes/xgeva-epar-product-information-tracked-changes_lv.docx)

lietuvių kalba (LT) (5.45 MB - DOCX)

**First published:**

29/07/2025

[View](/lt/documents/product-information-tracked-changes/xgeva-epar-product-information-tracked-changes_lt.docx)

magyar (HU) (5.46 MB - DOCX)

**First published:**

29/07/2025

[View](/hu/documents/product-information-tracked-changes/xgeva-epar-product-information-tracked-changes_hu.docx)

Malti (MT) (5.44 MB - DOCX)

**First published:**

29/07/2025

[View](/mt/documents/product-information-tracked-changes/xgeva-epar-product-information-tracked-changes_mt.docx)

Nederlands (NL) (5.44 MB - DOCX)

**First published:**

29/07/2025

[View](/nl/documents/product-information-tracked-changes/xgeva-epar-product-information-tracked-changes_nl.docx)

norsk (NO) (5.44 MB - DOCX)

**First published:**

29/07/2025

[View](/no/documents/product-information-tracked-changes/xgeva-epar-product-information-tracked-changes_no.docx)

polski (PL) (5.45 MB - DOCX)

**First published:**

29/07/2025

[View](/pl/documents/product-information-tracked-changes/xgeva-epar-product-information-tracked-changes_pl.docx)

português (PT) (5.45 MB - DOCX)

**First published:**

29/07/2025

[View](/pt/documents/product-information-tracked-changes/xgeva-epar-product-information-tracked-changes_pt.docx)

română (RO) (5.45 MB - DOCX)

**First published:**

29/07/2025

[View](/ro/documents/product-information-tracked-changes/xgeva-epar-product-information-tracked-changes_ro.docx)

slovenčina (SK) (5.45 MB - DOCX)

**First published:**

29/07/2025

[View](/sk/documents/product-information-tracked-changes/xgeva-epar-product-information-tracked-changes_sk.docx)

slovenščina (SL) (5.44 MB - DOCX)

**First published:**

29/07/2025

[View](/sl/documents/product-information-tracked-changes/xgeva-epar-product-information-tracked-changes_sl.docx)

Suomi (FI) (5.45 MB - DOCX)

**First published:**

29/07/2025

[View](/fi/documents/product-information-tracked-changes/xgeva-epar-product-information-tracked-changes_fi.docx)

svenska (SV) (5.44 MB - DOCX)

**First published:**

29/07/2025

[View](/sv/documents/product-information-tracked-changes/xgeva-epar-product-information-tracked-changes_sv.docx)

#### More information on Xgeva

- [EMEA-000145-PIP01-07-M09 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-000145-pip01-07-m09)
- [EMEA-000145-PIP02-12-M05 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-000145-pip02-12-m05)
- [Xgeva - withdrawal of application for variation to marketing authorisation](/en/medicines/human/variation/xgeva)
- [Prospective Observational Non-interventional Study to Describe Characteristics and Management of Patients With Giant Cell Tumor of Bone Treated With XGEVA and Its Use in Routine Clinical Practice in France (20150360) - post-authorisation study](https://catalogues.ema.europa.eu/study/22265)
- [The use and safety of XGEVA or Zoledronic acid in clinical practice among Chinese patients with bone metastases from breast, lung, or prostate cancer - a retrospective cohort study within Taiwan's Health Insurance Research Database (20190412) - post-authorisation study](https://catalogues.ema.europa.eu/study/46008)
- [A two-stage, prospective observational study describing the use and effectiveness of XGEVA®/ANJIAWEI® for the prevention of skeletal related events in patients with bone metastases from solid tumors relative to ZOMETA® in the People's Republic of China (20190036) - post-authorisation study](https://catalogues.ema.europa.eu/study/105058)
- [Estimation of Off-Label Use of XGEVA® (denosumab) Using Population-Based Databases in Denmark (20101335) - post-authorisation study](https://catalogues.ema.europa.eu/study/20211)
- [Effectiveness, Efficacy, and Safety of XGEVA (denosumab) in Chinese Patients With Giant Cell Tumor of Bone (GCTB): A Systematic Literature Review (20220044) - post-authorisation study](https://catalogues.ema.europa.eu/study/50352)
- [Prospective observational study to describe routine use of XGEVAâ for prevention of skeletal related events (SREs) in subjects with bone metastases from prostate carcinoma in Bulgaria (20180095) - post-authorisation study](https://catalogues.ema.europa.eu/study/48138)
- [Postmarketing Surveillance Study of XGEVA (Denosumab) in South Korea (20160198) - post-authorisation study](https://catalogues.ema.europa.eu/study/40681)
- [A Non-interventional Pharmacovigilance Study of Osteonecrosis of the Jaw and Infection Leading to Hospitalization Among Patients With Cancer Treated With XGEVA™ or Zoledronic Acid in Sweden, Denmark, and Norway (20101363) - post-authorisation study](https://catalogues.ema.europa.eu/study/36664)
- [Incidence of new Primary Malignancies Among Patients With Bone Metastases From Breast, Prostate, or Lung Cancer Treated With XGEVA or Intravenous Zoledronic Acid: a Retrospective Cohort Study (20170728) - post-authorisation study](https://catalogues.ema.europa.eu/study/33874)

#### Topics

- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 29/07/2025

## Share this page

[Back to top](#main-content)